EP. 1: Introduction: Chemotherapies for Advanced Breast Cancer
EP. 2: Nab-Paclitaxel in Metastatic Breast Cancer
EP. 3: Exceptional Responders in Breast Cancer
EP. 4: First-Line Treatment of HER2-Positive MBC
EP. 5: HER2 Testing Challenges in Metastatic Breast Cancer
EP. 6: Upfront T-DM1 in HER2-Positive Breast Cancer
EP. 7: Utilizing pCR in Breast Cancer Trials
EP. 8: Fitting T-DM1 Into Established Upfront Treatment Paradigms
EP. 9: T-DM1 Plus Pertuzumab in the MARIANNE Trial
EP. 10: Frontline Treatment of ER-Positive Breast Cancer
EP. 11: Second-Line Everolimus in Metastatic Breast Cancer
EP. 12: Managing the Toxicity of Everolimus in Breast Cancer
EP. 13: Adjuvant Everolimus and CDK4/6 Trials in Breast Cancer
EP. 14: TEXT/SOFT Findings in HR-Positive Breast Cancer
EP. 15: Utilizing Bisphosphonates in Breast Cancer
Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL
Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment
Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer
Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
